Date of Abstract presentation10th December 2023IndicationsDiffuse Large B-cell lymphoma (DLBCL)Abstract Number436Abstract typeOral
Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing. The primary analysis of the Phase II trial presented at the ASH 2023 demonstrated that, among 127 DLBCL patients treated with odronextamab, the reported objective response rate (ORR) was 52%, with 31% achieving a complete response (CR). Moreover, the responses were observed across high-risk subgroups, including those with International Prognosis...
